Rabbit Recombinant Monoclonal PIAS1 antibody. Carrier free. Suitable for IHC-P, ICC/IF, WB and reacts with Human, Recombinant full length protein - Human samples.
pH: 7.2 - 7.4
Constituents: PBS
IHC-P | ICC/IF | WB | |
---|---|---|---|
Human | Tested | Tested | Tested |
Mouse | Predicted | Predicted | Predicted |
Rat | Predicted | Predicted | Predicted |
Recombinant full length protein - Human | Not recommended | Not recommended | Tested |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes Perform heat-mediated antigen retrieval via the pressure cooker method before commencing with IHC staining protocol. |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Recombinant full length protein - Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Recombinant full length protein - Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Recombinant full length protein - Human, Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat | Dilution info - | Notes - |
Functions as an E3-type small ubiquitin-like modifier (SUMO) ligase, stabilizing the interaction between UBE2I and the substrate, and as a SUMO-tethering factor (PubMed:11583632, PubMed:11867732, PubMed:14500712, PubMed:21965678, PubMed:36050397). Catalyzes sumoylation of various proteins, such as CEBPB, MRE11, MTA1, PTK2 and PML (PubMed:11583632, PubMed:11867732, PubMed:14500712, PubMed:21965678, PubMed:36050397). Plays a crucial role as a transcriptional coregulation in various cellular pathways, including the STAT pathway, the p53 pathway and the steroid hormone signaling pathway (PubMed:11583632, PubMed:11867732). In vitro, binds A/T-rich DNA (PubMed:15133049). The effects of this transcriptional coregulation, transactivation or silencing, may vary depending upon the biological context (PubMed:11583632, PubMed:11867732, PubMed:14500712, PubMed:21965678, PubMed:36050397). Mediates sumoylation of MRE11, stabilizing MRE11 on chromatin during end resection (PubMed:36050397). Sumoylates PML (at 'Lys-65' and 'Lys-160') and PML-RAR and promotes their ubiquitin-mediated degradation (By similarity). PIAS1-mediated sumoylation of PML promotes its interaction with CSNK2A1/CK2 which in turn promotes PML phosphorylation and degradation (By similarity). Enhances the sumoylation of MTA1 and may participate in its paralog-selective sumoylation (PubMed:21965678). Plays a dynamic role in adipogenesis by promoting the SUMOylation and degradation of CEBPB (By similarity). Mediates the nuclear mobility and localization of MSX1 to the nuclear periphery, whereby MSX1 is brought into the proximity of target myoblast differentiation factor genes (By similarity). Also required for the binding of MSX1 to the core enhancer region in target gene promoter regions, independent of its sumoylation activity (By similarity). Capable of binding to the core enhancer region TAAT box in the MYOD1 gene promoter (By similarity). (Microbial infection) Restricts Epstein-Barr virus (EBV) lytic replication by acting as an inhibitor for transcription factors involved in lytic gene expression (PubMed:29262325). The virus can use apoptotic caspases to antagonize PIAS1-mediated restriction and express its lytic genes (PubMed:29262325).
PIAS2
DDXBP1, PIAS1, E3 SUMO-protein ligase PIAS1, DEAD/H box-binding protein 1, E3 SUMO-protein transferase PIAS1, Gu-binding protein, Protein inhibitor of activated STAT protein 1, RNA helicase II-binding protein, GBP
Rabbit Recombinant Monoclonal PIAS1 antibody. Carrier free. Suitable for IHC-P, ICC/IF, WB and reacts with Human, Recombinant full length protein - Human samples.
pH: 7.2 - 7.4
Constituents: PBS
ab247490 is the carrier-free version of Anti-PIAS1 + PIAS2 antibody [EPR2581Y] ab77231.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. The carrier-free buffer and high concentration allow for increased conjugation efficiency.
This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
This product is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar® is a trademark of Fluidigm Canada Inc.
PIAS1 and PIAS2 are known as Protein Inhibitors of Activated STAT. PIAS1 has a mass of approximately 72 kDa while PIAS2 is around 66 kDa. These proteins are present in the nucleus and they regulate various transcription factors. They achieve this by attaching SUMO (Small Ubiquitin-like Modifier) proteins to specific substrates a process called SUMOylation. Both PIAS1 and PIAS2 express in various tissues but expression levels can vary with cell type and physiological conditions.
PIAS1 and PIAS2 proteins play roles in the regulation of gene transcription. They can form complexes with several transcription factors and alter their activity by SUMOylating them. This modification is important because it changes how these transcription factors interact with DNA and other proteins. PIAS proteins sometimes act as co-regulators by either enhancing or repressing transcription factor function. This dual ability influences cellular processes like cytokine signaling and the immune response.
PIAS1 and PIAS2 participate in the JAK-STAT signaling pathway which is critical for transmitting signals from cytokines to the cell nucleus. It involves the activation of STAT family proteins such as STAT1 and STAT3. PIAS proteins add a layer of regulation influencing cell growth and differentiation. Another pathway connected with these proteins is the p53 pathway where PIAS1 can interact with p53 to regulate apoptosis and cell cycle arrest. These interactions indicate the versatile roles of PIAS proteins in cellular homeostasis.
PIAS1 and PIAS2 have links to cancer and autoimmune diseases. For example abnormal sumoylation mediated by these proteins can contribute to oncogenesis by disrupting normal cell cycle control involving key players like p53. In autoimmune conditions PIAS proteins may alter immune response through changes in inflammation-related genes. Knowing the interaction of PIAS proteins with transcription factors such as STAT1 helps to understand the complex gene regulation changes in these diseases.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
This data was developed using Anti-PIAS1 + PIAS2 antibody [EPR2581Y] ab77231, the same antibody clone in a different buffer formulation.
Blocking and dilution buffer: 5% NFDM/TBST.
Exposure times: Lane 1: 10 seconds, Lane 2: 5 seconds, Lane 3: 3 minutes.
Human PIAS1 full-length recombinant protein (ab152888)
All lanes: Western blot - Anti-PIAS1 + PIAS2 antibody [EPR2581Y] (Anti-PIAS1 + PIAS2 antibody [EPR2581Y] ab77231) at 1/50000 dilution
Lane 1: Human PIAS1 full-length recombinant protein with GST-Tag at 0.015 µg
Lane 2: Human PIAS2-beta recombinant protein fragment with GST-His-Tag at 0.015 µg
Lane 3: Human PIAS3 recombinant protein fragment with SUMO-His-Tag at 0.015 µg
All lanes: Western blot - Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/20000 dilution
Predicted band size: 72 kDa
Observed band size: 42 kDa, 98 kDa
This data was developed using Anti-PIAS1 + PIAS2 antibody [EPR2581Y] ab77231, the same antibody clone in a different buffer formulation.
All lanes: Western blot - Anti-PIAS1 + PIAS2 antibody [EPR2581Y] (Anti-PIAS1 + PIAS2 antibody [EPR2581Y] ab77231) at 1/50000 dilution
Lane 1: Daudi cell lysate at 10 µg
Lane 2: 293 cell lysate at 10 µg
Lane 3: Jurkat cell lysate at 10 µg
Lane 4: SW40 cell lysate at 10 µg
Lane 5: HepG2 cell lysate at 10 µg
All lanes: HRP labelled goat anti-rabbit at 1/2000 dilution
Predicted band size: 72 kDa
Observed band size: 78 kDa
This data was developed using Anti-PIAS1 + PIAS2 antibody [EPR2581Y] ab77231, the same antibody clone in a different buffer formulation.Immunocytochemistry/Immunofluorescence analysis of HeLa (human cervix adenocarcinoma) cells labelling PIAS1 + PIAS2 with purified Anti-PIAS1 + PIAS2 antibody [EPR2581Y] ab77231 at 1/500. Cells were fixed with 4% Paraformaldehyde and permeabilized with 0.1% Triton X-100. Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) ab150077, Alexa Fluor® 488-conjugated goat anti-rabbit IgG (1/1000) was used as the secondary antibody. Nuclei were counterstained with DAPI (blue). Secondary Only Control: PBS was used instead of the primary antibody as the negative control.
This data was developed using Anti-PIAS1 + PIAS2 antibody [EPR2581Y] ab77231, the same antibody clone in a different buffer formulation.Anti-PIAS1 + PIAS2 antibody [EPR2581Y] ab77231, at a 1/100 dilution, staining PIAS1 + PIAS2 in paraffin embedded human tonsil tissue by Immunohistochemistry. Perform heat mediated antigen retrieval via the pressure cooker method before commencing with IHC staining protocol.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com